Dose proportionality of roflumilast after single oral administration of 125 mg, 250 mg or 500 mg roflumilast - an open, randomized, three-period change-over study

*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting [email protected].

An open-label, randomized, three-period crossover study in healthy subjects.